c-Myc deregulation induces mRNA capping enzyme dependency by Lombardi, Olivia et al.
                                                              
University of Dundee
c-Myc deregulation induces mRNA capping enzyme dependency
Lombardi, Olivia; Varshney, Dhaval; Phillips, Nicola M.; Cowling, Victoria
Published in:
Oncotarget
DOI:
10.18632/oncotarget.12701
Publication date:
2016
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Lombardi, O., Varshney, D., Phillips, N. M., & Cowling, V. H. (2016). c-Myc deregulation induces mRNA capping
enzyme dependency. Oncotarget, 7(50), 82273-82288. DOI: 10.18632/oncotarget.12701
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. Feb. 2017
Oncotarget82273www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/             Oncotarget, 2016, Vol. 7, (No. 50), pp: 82273-82288
c-Myc deregulation induces mRNA capping enzyme dependency
Olivia Lombardi1, Dhaval Varshney1, Nicola M. Phillips1,2 and Victoria H. Cowling1
1 Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK
2 School of Science and the Environment, Manchester Metropolitan University, Manchester, M15 6BH, UK
Correspondence to: Victoria H. Cowling, email: v.h.cowling@dundee.ac.uk
Keywords: c-Myc, mRNA cap, transcription, translation, cell proliferation
Received: October 04, 2016 Accepted: October 10, 2016 Published: October 16, 2016
ABSTRACT
c-Myc is a potent driver of many human cancers.  Since strategies for directly 
targeting c-Myc protein have had limited success, upstream regulators and 
downstream effectors of c-Myc are being investigated as alternatives for therapeutic 
intervention.  c-Myc regulates transcription and formation of the mRNA cap, which is 
important for transcript maturation and translation.  However, the direct mechanism 
by which c-Myc upregulates mRNA capping is unclear.  mRNA cap formation initiates 
with the linkage of inverted guanosine via a triphosphate bridge to the first transcribed 
nucleotide, catalysed by mRNA capping enzyme (CE/RNGTT).  Here we report that 
c-Myc increases the recruitment of catalytically active CE to RNA polymerase II and 
to its target genes.  c-Myc-induced target gene expression, cell proliferation and 
cell transformation is highly dependent on CE, but only when c-Myc is deregulated.  
Cells retaining normal control of c-Myc expression are insensitive to repression of 
CE.  c-Myc expression is also dependent on CE.  Therefore, inhibiting CE provides an 
attractive route for selective therapeutic targeting of cancer cells which have acquired 
deregulated c-Myc. 
INTRODUCTION
c-myc is an essential gene required for cell 
growth and proliferation [1, 2]. In response to growth 
factor signalling c-Myc is upregulated and promotes 
the expression of genes which drive cell proliferation. 
Under homeostatic conditions the c-myc gene is tightly 
regulated. However, c-myc is deregulated in over half of 
human cancers, which directly contributes to oncogenic 
transformation [3, 4]. 
c-Myc is a basic helix-loop-helix leucine 
zipper (bHLH-LZ) transcription factor which forms 
a heterodimer with Max, another bHLH-LZ protein. 
In this complex, c-Myc binds to E-box sequences 
proximal to transcription initiation sites and regulates 
the transcription of target genes [5, 6]. c-Myc increases 
transcription by recruiting histone acetyltransferases 
and RNA polymerase II (RNA pol II) kinases [7-11]. In 
addition, a subset of genes is suppressed by c-Myc using 
various mechanisms, including displacement or inhibition 
of other transcriptional regulators, recruitment of histone 
deacetylases and activation of Ezh2 methyltransferase [2, 
12, 13].
Global analyses revealed that c-Myc regulates 
transcription of 10-15% of all genes [2, 14, 15]. The 
genes regulated by c-Myc vary between cell types with 
the exception of a core signature of genes which promote 
cell growth, including those involved in ribosomal 
biogenesis, nucleolar function and RNA processing [16, 
17]. c-Myc also directly promotes RNA polymerase I 
and III-dependent transcription [18]. When expressed at 
oncogenic levels, c-Myc binding specificity becomes less 
stringent and it regulates all actively transcribed genes, 
although less so than its canonical targets [19, 20]. The 
model emerges that c-Myc deregulation directly regulates 
a subset of genes and causes amplification of general 
transcription and translation, ultimately increasing the 
propensity of cells to undergo oncogenic transformation 
[16, 19, 21].
c-Myc-dependent RNA pol II phosphorylation has 
the potential to regulate recruitment of factors important 
for transcription and mRNA processing to its targets genes 
[7, 8, 22-25]. Factors that promote transcription initiation, 
elongation, mRNA capping, splicing and transcription 
termination are recruited to the phosphorylated C-terminal 
domain of RNA pol II. c-Myc regulates formation of the 
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mRNA cap on its target transcripts, which contributes to 
c-Myc-dependent gene expression and cell proliferation 
[8, 26, 27]. The mRNA cap is 7-methylguanosine linked to 
the first transcribed nucleotide, a structure which protects 
transcripts from degradation, promotes splicing and 3’ end 
processing, facilitates nuclear export of mRNA, and aids 
loading of mRNAs onto ribosomes for translation [28]. 
The direct mechanism by which c-Myc promotes 
mRNA capping is unclear. The enzyme which initiates 
cap formation, mRNA capping enzyme (CE/RNGTT), 
specifically binds to the RNA pol II CTD when 
phosphorylated on Ser-5, spatially and temporally 
localising the enzyme to act on nascent transcripts [29-34]. 
CE has triphosphatase and guanylyltransferase activites 
which act sequentially to add the guanosine cap structure 
to transcripts. CE triphosphatase cleaves the terminal 
phosphate from the first transcribed nucleotide and CE 
guanylyltransferase transfers guanosine mono-phosphate 
(GMP) to the transcript 5’ end, creating the guanosine-
capped structure. Ser-5 phosphorylated RNA pol II CTD 
also activates CE guanylyltransferase activity in vitro [35]. 
The final step in basic cap formation is catalysed by RNA 
guanine-7 methyltransferase (RNMT), which methylates 
the guanosine moiety at the N7 position. RNMT is also 
recruited to transcription initiation sites, probably via the 
phosphorylated RNA pol II CTD, since recruitment is 
diminished by CTD kinase inhibitors [30, 36]. Although 
CE and RNMT are recruited to phosphorylated RNA pol 
II, to date, their recruitment has not been demonstrated to 
be c-Myc-dependent. c-Myc-dependent cap methylation 
requires upregulation of the c-Myc target gene S-adenosyl 
homocysteine hydrolase, (SAHH) [27]. SAHH hydrolyses 
the inhibitory by-product of methylation reactions, SAH, 
thus enhancing mRNA cap methylation. However, 
increased expression of SAHH alone is not able to elevate 
mRNA cap formation and therefore c-Myc-dependent 
SAHH upregulation permits rather than promotes cap 
formation. 
We investigated the relationship between c-Myc 
and CE. We found that c-Myc increases the recruitment 
of CE to RNA pol II and to proximal promoter regions. 
Deregulated c-Myc is highly dependent on CE to 
drive gene expression and cell proliferation, whereas 
endogenous c-Myc is not. We also report that the 
expression of deregulated and endogenous c-Myc is 
dependent on CE. 
RESULTS
c-Myc deregulation increases the interaction of 
RNA pol II with CE
To investigate the relationship between c-Myc 
and mRNA capping, we determined the impact of c-myc 
deregulation on the proteins with which capping enzyme 
(CE) interacts. This analysis was performed in human 
immortalised mammary epithelial cells (IMECs), which 
are non-transformed and exhibit many normal growth 
controls [37]. Deregulation of c-Myc transforms IMECs, 
resulting in elevated proliferation rate and anchorage-
independent growth [38]. Retroviral infection was used 
to create IMEC lines which express elevated levels of 
c-Myc or vector control, designated IMEC/c-Myc or 
IMEC/vec, respectively. A second round of infection 
resulted in stable expression of CE-GFP (C-terminal GFP 
fusion) or the empty vector control (INI). Equivalent 
levels of CE-GFP were expressed in IMEC/c-Myc and 
IMEC/vec and CE-GFP expression did not alter c-Myc 
expression (Figure 1A). CE-GFP complexes were 
immunoprecipitated from IMEC lines via the GFP tag 
and resolved by SDS-PAGE. Mass spectrometry was 
used to identify CE-GFP-interacting proteins, which 
included RNA polymerase II large subunit (RNA pol II), 
a previously observed CE-interacting protein (Figure 1B)
[31, 33, 39]. Increased c-Myc expression resulted in more 
RNA pol II being purified with CE-GFP (Figure 1B). To 
confirm this observation, endogenous CE complexes were 
immunoprecipitated from IMEC/c-Myc and IMEC/vec 
(Figure 1C and 1D). As observed previously, deregulation 
of c-Myc resulted in increased RNA pol II C-terminal 
domain (CTD) Ser-5 phosphorylation [8]. Deregulated 
c-Myc expression resulted in increased interaction of CE 
with phospho-Ser 5 RNA pol II, observed using phospho-
specific and pan RNA pol II antibodies. Previous studies 
reported that Spt5, a mediator of RNA pol II elongation, 
binds to RNA pol II and CE [40-42]. Elevated c-Myc 
expression also increased the interaction of CE with Spt5, 
which may be direct or via RNA pol II.
Since c-Myc increases RNA pol II Ser-5 
phosphorylation, which recruits CE and activates the 
guanylyltransferase, we investigated whether c-Myc 
increases CE activity [29, 35]. CE hydrolyses GTP to 
produce the GMP donor for the cap guanylylation reaction. 
Formation of the CE-GMP intermediate is used as an 
approximation of guanylyltransferase activity (Figure 
1E) [35]. CE was immunoprecipitated from IMEC/c-Myc 
or IMEC/vec nuclear extracts and [α-32P]GTP supplied 
as the substrate, resulting in formation of a CE-[32P]
GMP intermediate which was resolved by SDS-PAGE 
and quantified by phosphorimager (Figure 1F and 1G). 
Elevated c-Myc expression did not detectably alter total 
nuclear CE-GMP. However, only a fraction of CE is RNA 
pol II-bound and since it is this which catalyses capping, 
RNA pol II-associated guanylyltransferase activity was 
analysed. RNA pol II was immunoprecipitated from 
IMEC/c-Myc and IMEC/vec extracts and co-purifying 
CE-GMP complexes detected (Figure 1H). Elevated 
expression of c-Myc caused an increase in CE-GMP 
associated with RNA pol II, indicating that the CE 
recruited is active. In summary, c-Myc increases the 
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Figure 1: c-Myc increases the interaction of CE with RNA pol II. (A) Protein extracts from IMEC/vec and IMEC/c-Myc, 
expressing CE-GFP or empty vector (INI) were analysed by Western blotting. (B) CE-GFP complexes were immunoprecipitated, resolved 
by SDS-PAGE and Coomassie-stained. Mass spectrometry was used to identify proteins. (C) CE complexes were immunoprecipitated from 
IMEC/vec and IMEC/c-Myc and analysed by Western blotting. FLAG antibody used as a control (ctrl IP). Input and immunoprecipitation 
(IP) panels are different exposures of the same Western blots. (D) ImageJ software was used to quantify Western blot signal for S5p-RNA 
pol II, RNA pol II pan and Spt5 in CE IP, normalised to CE. Error bars represent standard error of the mean, n=4 (S5p-RNA pol II) or n=2 
(RNA Pol II and Spt5). (E) CE hydrolyses [α-32P] GTP, yielding a 32P-labelled CE-GMP intermediate, an approximation of CE activity. (F) 
CE IPs from nuclear extracts of IMEC/vec and IMEC/c-Myc were incubated with [α-32P]GTP, resolved by SDS-PAGE and 32P detected 
by phosphorimager. (G) Signal quantified by phosphoimager. Error bars represent standard error of the mean, n=5. (H) RNA pol II was 
immunoprecipitated from IMEC/vec and IMEC/c-Myc and 32P-GMP binding detected by phosphoimager. CE-32P-GMP signal normalised 
to RNA pol II (detected by Western blot). Error bars represent standard error of the mean, n=4. Significance relative to control calculated 
by Student’s T-test; * = p≤0.05, *** = p≤0.001.
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recruitment and activation of CE.
c-Myc promotes CE recruitment to c-Myc target 
genes
Since c-Myc increases the interaction of RNA pol 
II and CE, we investigated whether increasing c-Myc 
expression increases CE recruitment to target genes. CE 
recruitment was investigated in IMECs using chromatin 
immunoprecipitation (ChIP), however CE binding 
was below the limit of detection. As an alternative CE 
recruitment to c-Myc target genes was investigated in 
HeLa cells, which express high levels of deregulated 
c-Myc. In order to identify c-Myc target genes, Hela 
cells were transfected with c-Myc siRNA, which resulted 
in a decrease in c-Myc and phospho-Ser-5 RNA pol II 
(Figure 2A). A selection of target genes was analysed by 
RT-qPCR to identify the most c-Myc-responsive (Figure 
2B). Nucleolin (NCL), fibrillarin (FBL) and nucleoside 
diphosphate kinase A (NME1) transcripts were the most 
significantly reduced in response to c-Myc suppression 
and thus the recruitment of CE to these genes was 
analysed by ChIP. CE binding to regions surrounding the 
transcription start site (TSS) and c-Myc-binding sites was 
analysed by qPCR (Figure 2C). Binding of CE to GAPDH 
TSS was also analysed. CE was found at the TSS of c-Myc 
target genes and proximally upstream. c-Myc depletion 
Figure 2: c-Myc regulates CE recruitment to c-Myc target genes. (A) HeLa cells transfected with c-Myc siRNA or a non-
targeting control for 24 hours were analysed by Western blotting. (B) c-Myc target genes transcript level, normalised to GAPDH, were 
determined by RT-qPCR in HeLa cells transfected with c-Myc siRNA or non-targeting control for 48-72 hours. Error bars represent 
standard error of the mean, n≥3. (C) Chromatin immunoprecipitation assay (ChIP) was performed using anti-CE antibody or control, in 
HeLa cells transfected with c-Myc siRNA or non-targeting control for 24 hours. c-Myc target genes (NCL, FBL and NME1), and GAPDH 
in ChIPs were analysed by qPCR. CE ChIP signal was expressed as fold enrichment over control ChIP signal. Schematics depict regions of 
primer amplification relative to the TSS (arrow) and E-box sequence(s) (bold band). Error bars represent standard error of the mean, n≥3. 
Significance calculated by Student’s T-test; * = p≤0.05, ** = p≤0.01, *** = p≤0.001.
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resulted in a decrease in CE binding to NCL, FBL, NME1 
and GAPDH. Distal regions of NCL and NME1 served as 
a negative control for the ChIP. CE recruitment to these 
distal sites was low (~2-fold over background) and not 
c-Myc-responsive. 
c-Myc expression is dependent on CE
Since c-Myc regulates the recruitment of CE to 
its target genes, we investigated the dependency of their 
expression on CE. IMEC/c-Myc and IMEC/vec were 
transfected with CE siRNA resulting in CE transcripts and 
protein being depleted (Figures 3A and 3B). CE depletion 
resulted in a substantial reduction in the expression of 
Figure 3: c-Myc expression is CE-dependent. (A) IMEC/vec and IMEC/c-Myc were transfected with CE siRNA or non-targeting 
control for 72hrs. CE transcript expression normalised to GAPDH was determined by RT-qPCR. Error bars represent standard error of the 
mean, n=3 (B) IMEC/vec and IMEC/c-Myc transfected with CE siRNA (+) or non-targeting control (-) for 72hrs. Protein was analysed by 
Western blotting. (C) Densitometry was performed to quantify the decrease in c-Myc Western blot signal (normalised to actin) following 
CE depletion, relative to control transfection. Error bars represent standard error of the mean, n=6. (D) IMEC/vec and IMEC/c-Myc were 
stably transduced with GFP or a CE-GFP construct containing wobble codons to confer resistance to CE siRNA. Cells were transfected 
with CE siRNA (+) or control (-) and protein analysed by Western blot. (E) HeLa cells were transfected with two independent CE siRNAs 
(#1 or #2) or non-targeting control (-) for 72hrs. Protein analysed by Western blotting. (F) IMEC/vec, IMEC/c-Myc and HeLa cells 
were transfected with CE siRNA or non-targeting control. Endogenous c-Myc and Flag-c-Myc transcript level normalised to GAPDH 
was determined by RT-qPCR. Error bars represent standard error of the mean, n≥6. Significance relative to control siRNA calculated by 
Student’s T-test, *** = p≤0.001; ** = p≤0.01; * = p≤0.05.
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endogenous c-Myc in IMEC/vec and exogenous c-Myc 
in IMEC/c-Myc (Figures 3B and C), which was rescued 
by expressing siRNA-resistant CE-GFP (Figure 3D). 
Reduced c-Myc expression was also observed in HeLa 
cells in response to transfection of two independent CE 
siRNAs (Figure 3E). Depletion of CE caused a reduction 
in endogenous c-Myc transcript levels in IMEC/vec and 
HeLa cells, and a reduction in exogenous c-Myc (FLAG-
Figure 4: c-Myc-induced gene expression is CE-dependent. (A) IMEC/vec and IMEC/c-Myc were transfected with CE siRNA 
or non-targeting control for 72hrs. c-Myc target gene transcripts were analysed by RT-qPCR, performed with equivalent amounts of RNA. 
Error bars represent standard error of the mean, n≥3. (B) IMEC/vec and IMEC/c-Myc expressing either GFP or CE-GFP (resistant to CE 
siRNA) were transfected with CE siRNA or control and transcripts analysed by RT-qPCR. Error bars represent standard error of the mean, 
n=4. (C) Average change in expression of c-Myc target genes (NCL, ODC, FBL, NME1, NPM and TIP49) upon CE depletion relative 
to control transfections. Error bars represent standard error of the mean, n=6. (D) IMEC/vec and IMEC/c-Myc were transfected with CE 
siRNA or non-targeting control for 72hrs. Protein analysed by Western blotting. (E) Densitometry performed to quantify the nucleolin 
(NCL) Western blot signal (normalised to actin) following CE depletion in IMEC/vec and IMEC/c-Myc. Error bars represent standard error 
of the mean, n≥3. Significance calculated by Student’s T-test, *** = p≤0.001; ** = p≤0.01; * = p≤0.05.
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Myc) in IMEC/c-Myc. (Figure 3F). This suggests that 
reducing capping impacts the transcription or stability 
of c-Myc transcripts. Since exogenous c-Myc in IMECs 
is expressed without its endogenous promoter and 
untranslated regions, mechanisms involving the coding 
region determinant of c-Myc transcript stability may 
render it sensitive to degradation upon CE depletion [43, 
44].
Deregulation of c-Myc increases target gene 
dependency on CE 
The dependency of c-Myc target gene expression 
on CE was investigated using CE siRNA. Repressing 
CE expression will inhibit CE as a mediator of c-Myc 
function and as a controller of c-Myc expression, and 
have additional effects on gene expression. IMEC/c-Myc 
and IMEC/vec were transfected with CE siRNA and 
c-Myc target genes expression analysed by RT-qPCR 
(Figure 4A). NCL, ODC, FBL, NME1, NPM, FBL and 
TIP49 were verified as c-Myc-induced genes in IMECs. 
For these verified c-Myc target genes, the increase in 
expression induced by deregulated c-Myc was abolished 
by CE depletion. However, c-Myc target genes were 
unaffected by CE depletion in IMEC/vec, which only 
express endogenous c-myc. This was surprising given 
that endogenous c-Myc expression is impaired by CE 
knockdown and multiple independent experiments showed 
that CE levels are equivalently depleted in IMEC/vec and 
IMEC/c-Myc (Figure 3B and 3C). Expression of siRNA-
resistant CE-GFP rescued the defect in c-Myc target 
gene expression in IMEC/c-Myc observed in response to 
CE suppression (Figure 4B, three representative genes, 
and Figure 4C, average result for 6 genes). GAPDH 
exhibited similar responses to CE suppression as the 
canonical c-Myc targets, suggesting that the interplay of 
CE and c-Myc influences genes on a global scale, albeit 
to a lesser extent with non-canonical targets (Figure 4A). 
UBF (upstream binding factor), a previously described 
c-Myc target gene, was unresponsive to c-Myc and CE 
knockdown in IMECs, indicating that c-Myc and CE 
dependency has a degree of specificity (Figure 4A). 
CCND1 (cyclin D1) is a c-Myc-repressed gene in IMECs 
[45,46]. CCND1 transcript levels slightly increased when 
CE was depleted in IMEC/vec, correlating with reduced 
Figure 5: c-Myc target gene regulation in IMEC. (A) IMEC/vec were transfected with c-Myc siRNA or non-targeting control 
for 72hrs. Protein analysed by Western blotting. (B) The expression of c-Myc target gene transcripts analysed by RT-qPCR, relative to 
GAPDH. (C) IMEC/vec were transfected with non-targeting control, c-Myc siRNA or CE siRNA for 72hrs. Protein analysed by Western 
blotting. Significance calculated relative to control siRNA using Student’s T-test, ** = p≤0.01; * = p≤0.05.
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c-Myc protein (Figure 4A). However, when CCND1 
was repressed by elevated c-Myc expression, it was 
unresponsive to CE depletion, suggesting that sufficient 
c-Myc remains to maintain CCND1 repression. Western 
blots were performed to determine if CE depletion affected 
the protein level of c-Myc targets in IMECs (Figure 4D 
and 4E). Consistent with transcript levels, nucleolin 
protein expression was impaired by CE siRNA in IMEC/c-
Myc, but not in IMEC/vec. 
We investigated why target gene expression was 
unaffected when endogenous c-Myc levels were reduced 
in response to CE depletion. It was possible that the c-Myc 
target genes analysed are only induced by deregulated 
and not endogenous c-Myc in IMECs. To investigate 
this, IMECs were transfected with c-Myc siRNA and 
knockdown of endogenous c-Myc confirmed (Figure 5A). 
RNA pol II Ser-5 phosphorylation decreased in response 
to c-Myc suppression, indicating that endogenous c-Myc 
is functional in IMECs. NCL, ODC and TIP49 transcripts 
were insensitive to this level of endogenous c-Myc 
knockdown, whereas NME1, NPM and FBL transcript 
levels were sensitive (Figure 5B). c-Myc siRNA caused 
a greater decrease in c-Myc than CE siRNA (Figure 
5C). Therefore in IMEC/vec, NME1, NPM and FBL are 
target genes of endogenous c-Myc, but are resistant to the 
intermediate level of c-Myc depletion observed upon CE 
knockdown.
Suppression of deregulated c-Myc reduces target 
gene dependency on CE 
We investigated if c-Myc target gene expression is 
dependent on CE in HeLa cells, which have deregulated 
transcriptional activation of the c-myc gene due to viral 
insertion [47]. Cells were transfected with combinations 
of c-Myc and CE siRNAs or non-targeting controls, 
which resulted in efficient knockdown of both proteins 
(Figure 6A). c-Myc depletion was detected 24 hours after 
c-Myc-siRNA transfection whereas CE depletion was not 
detectable until 48 hours after CE siRNA transfection (data 
not shown). Therefore, in this experimental arrangement 
CE is depleted following changes in c-Myc protein level. 
As in IMECs, c-Myc expression was dependent on CE 
regardless of c-Myc levels, although this was more 
apparent in when c-Myc was repressed by transfection 
of c-Myc siRNA (Figure 6A and 6B). CE depletion in 
HeLa cells resulted in significant repression of c-Myc 
target genes (Figure 6C). When c-Myc was repressed, CE 
depletion resulted in reduced expression of some c-Myc 
target genes, but to a lesser extent than that in HeLa 
control cells which carry deregulated c-Myc (Figure 6C, 
specific genes; Figure 6D, average result for five genes). 
This indicates that deregulated c-Myc in HeLa cells causes 
enhanced dependency of c-Myc target genes on CE. As in 
IMECs, the c-Myc-repressed gene CCND1 was unaffected 
by CE depletion in cells expressing high levels of c-Myc.
We questioned whether CE knockdown only 
influences c-Myc target gene expression by regulating 
c-Myc. Transfection of CE siRNA in HeLa cells caused, 
on average, a ~20% reduction in c-Myc expression 
whereas c-Myc siRNA caused a 70% reduction (Figure 
6E). However, transfection of CE siRNA depletes c-Myc 
target gene expression to the same extent as transfection 
of c-Myc siRNA (Figure 6F, average decrease in 
expression of five genes). This suggests that CE does not 
control c-Myc target genes simply by regulating c-Myc 
expression; its role as a mediator of c-Myc function is also 
important. In addition, we note that other genes are likely 
to be sensitive to CE depletion which may also impact on 
c-Myc target genes. 
c-Myc-driven cell proliferation and 
transformation is dependent on CE
In epithelial cells, deregulated c-Myc increases 
cell proliferation and induces anchorage-independent 
cell growth, characteristics of many epithelial cancer 
cells. Since deregulation of c-Myc increases target 
gene dependency on CE, we investigated whether cell 
proliferation and anchorage-independent growth is 
also CE-dependent. Consistent with previous studies, 
deregulated c-Myc in IMECs increased cell proliferation 
(Figure 7A and 7B) [38]. IMEC/c-Myc and IMEC/vec 
were transfected with CE siRNA and cells counted after 
72 hours. IMEC/vec proliferation was unaffected by 
CE depletion, however, IMEC/c-Myc cell number was 
significantly reduced.
To determine whether CE depletion influences 
c-Myc-driven cell transformation, we performed 
anchorage-independent cell growth assays. The IMEC 
culture medium is serum-free, however anchorage-
independent growth assays require a supplement of 
fetal bovine serum (FBS) [45,48]. c-Myc increases the 
proliferation of IMECs to a similar extent in the presence 
or absence of FBS (Figure 7A and 7B). c-Myc expression 
was not altered by culturing cells in FBS (Figure 7C). In 
a previous study, CE depletion induced apoptosis in HeLa 
cells [49]. CE siRNA did not induce PARP cleavage in 
IMECs or morphological signs of apoptosis (Figure 7C, 
data not shown). The p21 and p27 tumour suppressor 
genes are c-Myc-repressed genes which negatively 
regulate the G1-S transition in the cell cycle [50]. p21 
and p27 were elevated by CE depletion in IMEC/c-Myc 
but not IMEC/vec (Figure 7D). This indicates that CE 
knockdown restrains c-Myc-driven cell cycle transit in 
IMECs.
IMEC/c-Myc and IMEC/vec were transfected with 
CE siRNA prior to the soft agar transformation assays 
which measure anchorage-independent cell proliferation. 
Deregulated c-Myc expression resulted in 45% IMECs 
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Figure 6: c-Myc depletion reduces target genes dependency on CE. (A) HeLa cells were transfected with CE siRNA, c-Myc 
siRNA and/or non-targeting control for 72hrs. Protein analysed by Western blotting. (B) Densitometry performed to quantify the decrease in 
c-Myc Western blot signal (normalised to actin), in response to CE depletion in HeLa cells, transfected with c-Myc siRNA or non-targeting 
control. Error bars represent standard error of the mean, n≥6. (C) c-Myc siRNA, CE siRNA and control transfections were performed for 
72 hours. c-Myc target gene transcripts were analysed by RT-qPCR, normalised to GAPDH. Error bars represent standard error of the 
mean, n=4. (D) Average change in c-Myc target gene transcripts (NCL, NME1, ODC, FBL and NPM) in response to CE siRNA, relative 
to control transfections. Error bars represent standard error of the mean, n=5. (E) Decrease in c-Myc Western blot signal following c-Myc 
and/or CE knockdown, relative to control transfection. Error bars represent standard error of the mean, n≥6. (F) Average decrease in c-Myc 
target gene transcripts (NCL, NME1, ODC, FBL and NPM) following c-Myc and/or CE knockdown, relative to control transfection. Error 
bars represent standard error of the mean, n=5. Significance was calculated by Student’s T-test, ***= p≤0.001; **= p≤0.01; *= p≤0.05. For 
B and D-F, significance relative to control siRNA.
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plated growing in anchorage-independent colonies 
(Figure 8A) [45,51]. CE depletion significantly reduced 
anchorage-independent colonies, including reducing the 
proportion of colonies over 50µm in diameter by 60% 
(Figure 8B and 8C). Therefore, CE is important for the 
incidence of c-Myc-dependent transformation and for 
subsequent colony growth. 
DISCUSSION
c-Myc is a potent oncogene and one of the most 
frequently deregulated in human cancers. The majority 
of selective cancer therapies function by targeting the 
active site of key enzymes with small molecule inhibitors. 
However, c-Myc has been a challenging target since it 
lacks an active site and as a result there has been sustained 
interest in its mode of action, particularly in its enzymatic 
co-factors. In this study we investigated the relationship 
between c-Myc and the mRNA capping enzyme CE/
RNGTT, which initiates mRNA cap formation by adding 
an inverted guanosine group to nascent transcripts. The 
mRNA cap protects the transcript from degradation during 
transcription and recruits processing and translation 
factors. We determined that deregulated c-Myc increases 
the interaction of CE and RNA pol II, increases CE 
recruitment to c-Myc target genes and increases the CE 
guanylyltransferase activity associated with RNA pol II. 
Furthermore, we observed that CE is important for c-Myc 
expression. Deregulation of c-myc co-ordinately promotes 
many major metabolic pathways in the cell resulting in 
enhanced cell proliferation and proliferation becoming 
somewhat independent of growth controls. In IMECs and 
HeLas, cell proliferation and transformation driven by 
deregulated c-Myc were found to be CE-dependent. 
Cells carrying deregulated c-Myc were significantly 
more dependent on CE for gene expression, cell 
proliferation and cell transformation than cells with low 
c-Myc expression. IMECs which express low endogenous 
c-Myc levels or HeLa cells in which c-Myc expression 
was supressed by siRNA were largely unaffected by 
transfection of CE siRNA. This was somewhat surprising 
given that endogenous and deregulated c-Myc expression 
Figure 7. CE depletion reduces c-Myc-dependent cell proliferation . (A) IMEC/vec and IMEC/c-Myc were transfected with CE siRNA or 
a non-targeting control and counted after 72 hours. Error bars represent standard error of the mean, n=3. (B) IMEC/vec and IMEC/c-Myc 
were maintained in growth medium supplemented with 5% FBS. Cells were transfected with CE siRNA or control and counted after 72hrs. 
Error bars represent standard error of the mean, n=3. (C) IMEC/vec and IMEC/c-Myc cultured with or without FBS were transfected with 
CE siRNA or control for 72hrs. Protein analysed by Western blotting. IMEC/c-Myc treated with 10µM MG123 for 24 hours as a positive 
control for apoptosis (#). (D) IMEC/vec and IMEC/c-Myc were transfected with CE siRNA or control and protein analysed by Western blot. 
Significance calculated by Student’s T-test, *** = p≤0.001; ** = p≤0.01; * = p≤0.05.
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is dependent on CE. Deregulated c-Myc results in a 
substantial increase in global transcription which may 
result in increased dependency on CE to maintain 
transcript processing. Several previous studies in cancer 
cells have shown that c-Myc expression thresholds 
govern distinct cellular responses [52-54]. The molecular 
mechanisms governing these c-Myc thresholds are likely 
to involve the availability of transcriptional co-factors and 
repressors.
Since the discovery that c-Myc regulates mRNA 
capping, studies have focussed on the involvement 
of RNMT, the N-7 guanosine cap methyltransferase, 
which completes the basic functional cap structure [8, 
55]. Mechanisms involving RNMT recruitment and 
methionine metabolism contribute to c-Myc-dependent 
cap methylation [8, 27]. Inhibition of RNMT function 
by blocking biproduct removal selectively targets cells 
carrying deregulated c-Myc. The discovery that c-Myc 
regulates recruitment of CE reveals that c-Myc is co-
ordinating all the basic mechanisms of mRNA cap 
formation. Inhibition of both guanosine cap addition 
and guanosine cap methylation selectively target cells 
with deregulated c-Myc, indicating that both steps in cap 
formation are critical for c-Myc function [8, 27].
Transcription and translation are considered 
attractive therapeutic avenues for targeting c-Myc-
driven cancers, since c-Myc deregulation increases 
global transcript and protein production [23, 25, 56-
Figure 8: CE is required for c-Myc-induced transformation. (A) IMEC/vec and IMEC/c-Myc maintained with 5% FBS were 
transfected with CE siRNA or a non-targeting control. After 72 hours cells were plated in suspension. Colonies scored using a graticule 
after 9-15 days. The percentage of cells forming colonies >20µm reported. Error bars represent standard error of the mean, n=3. (B) The 
percentage of cells forming colonies >50µm reported. Error bars represent standard error of the mean, n=3. (C) Micrographs taken one 
month after cells were plated in suspension. Scale bar represents 200µm. Significance calculated by Student’s T-test, ***p≤0.001; *p≤0.05.
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59]. Recent studies reported that many cancer cell lines 
are sensitive to Cdk7 inhibitors, which reduce RNA pol 
II Ser-5 phosphorylation [60, 61]. The CDK7 inhibitor 
THZ1 is highly effective in targeting models of c-Myc-
driven small cell lung carcinoma, neuroblastoma and 
triple-negative breast cancer [62-64]. Among its functions, 
THZ1 abolishes co-transcriptional mRNA capping, which 
may contribute to its efficacy [65]. Other components of 
the gene expression machinery are being investigated as 
therapeutic targets in c-Myc-driven cancers, including the 
splicing machinery and cap binding proteins. Components 
of the splicing machinery are direct targets of c-Myc and 
are essential in c-Myc-driven lymphamogenesis [66]. 
Other splicing components are synthetic lethal with 
overexpressed c-Myc [67]. Inhibiting the function and 
interactions of the translation initiation complex, eIF4F, 
interferes with cap-dependent translation and is also 
being investigated as a therapeutic strategy [68]. The 
data presented here demonstrate that deregulated c-Myc 
sensitises cells to inhibition of the Capping Enzyme, CE. 
Inhibiting CE targets c-Myc expression and function 
and therefore we suggest that CE should be investigated 
further as a therapeutic target. 
MATERIALS AND METHODS
Cell culture and manipulation
Cells maintained at 37°C/5% CO2 in humidified 
incubator. IMECs cultured according to [37], or 
supplemented with 5% FBS (see figure legends). HeLa 
cells cultured in Dulbecco’s modified eagle medium 
(DMEM)/10% FBS/2mM L-glutamine. PhoeNX cells 
cultured in DMEM/10% FBS/2mM L-glutamine/1mM 
sodium pyruvate. Cells counted in 0.2% trypan blue using 
Countess cell counter (Life technologies). For retroviral 
infection, 10cm plate PhoeNX cells transfected with 
4ug DNA using 8ug polyethylenimine. After 48hrs, viral 
supernatant 0.45μm filtered, mixed 1:1 with cell media 
and 5μg/ml polybrene and added to recipient cells. After 
24-72 hours cells selected with 150μg/ml hygromycin B 
(LXSH c-Myc constructs) or 500μg/ml G418 (pBMN-
IRES-Neo CE-GFP constructs). siRNA transfections 
performed using Lipofectamine RNAiMAX (Life 
Technologies). Dharmacon siRNAs used (non-targeting 
control: D-001210-03-50, c-Myc: D-003282-14-0050, CE 
#1: D-009782-01-0050 and CE #2: D-009782-02-0050). 
Cells transfected during seeding using 50nM siRNA or 
75nM for double target knockdowns. 
Cell extracts
Performed on ice/4°C. Cells lysed in F buffer 
(10mM Tris/Cl pH 7.5, 50mM NaCl, 30mM Na4 
pyrophosphate, 50mM NaF, 5μM ZnCl2, 10% glycerol, 
0.5% Triton x-100) supplemented with 1mM DTT, 1μM 
pepstatin, 10μM leupeptin, 0.1 trypsin inhibitor units 
aprotinin, 1% phosphatase inhibitor cocktail 2 and 3 
(all Sigma Aldrich). Protein concentration determined 
by Bradford assay. For nuclear extracts, cells swelled in 
Buffer A (10mM HEPES pH 7.9, 1.5mM MgCl2, 10mM 
KCl) and lysed by syringing with 27G needle. Nuclei 
centrifuged at 6000rpm for 10 minutes and lysed in F 
buffer.
Mass spectrometry
Performed by LC-MS-MS using linear ion trap-
orbitrap hybrid mass spectrometer (Orbitrap-Classic, 
Thermo) equipped with nanoelectrospray ion source 
(Thermo) and coupled to a Proxeon EASY-nLC system. 
Peptides prepared by in-gel tryptic cleavage were injected 
via 2cm trap column (Nano Separations, NS-MP-10 
BioSphere C18, 5μm, 120Å,360/100μm) onto Thermo 
(Part No. 160321) Acclaim PepMap100 reverse phase 
C183μm column, 75μm x 15cm, with 300 nl/min flow 
and eluted with linear gradient of 95% solvent A (2% 
Acetonitrile/0.1% formic acid/H2O) to 35% solvent B 
(90% acetonitrile/0.08% formic acid/H2O) at 20 minutes 
followed by rise to 80% B at 23 minutes, maintained 
at 80% B for 5 minutes, followed by re-equilibration. 
Instrument operated with ‘lock mass’ option to improve 
mass accuracy of precursor ions and data acquired in data-
dependent mode, automatically switching between MS 
and MS-MS acquisition. Full scan spectra (m/z 350-2000) 
acquired in orbitrap with resolution R=60,000 at m/z 400 
(after accumulation to FTMS Full AGC Target; 1,000,000; 
MSn AGC Target; 100,000). 5 most intense ions, above 
specified minimum signal threshold (5,000), based upon 
low resolution (R = 15,000) preview of the survey scan, 
fragmented by collision induced dissociation and recorded 
in linear ion trap, (Full AGC Target; 30,000. MSn AGC 
Target; 5,000). Proteins were identified and quantified 
using Maxquant software. RNA pol II mascot scores 3545 
and 2529.
Western blotting
Primary antibodies used: CE (in house); c-Myc 
(9402), Spt5 (9033) and PARP (9542) from Cell 
Signalling; tubulin (sc-9104), RNA pol II pan (sc-899) 
and p21 (sc-397) from Santa Cruz; RNA pol II S5-P CTD 
(3E8) from Chromotek; actin (ab3280) and p27 (ab32034) 
from Abcam; and SMC1 (A300-055A) and nucleolin 
(A300-711A) from Bethyl Laboratories.
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Immunoprecipitation
Immunoprecipitations (IPs) performed at 4°C in F 
buffer. CE-GFP co-IPs performed for 2.5 hours using GFP-
Trap_A (Chromotek). CE co-IPs performed for 2.5 hours 
with 2μg CE antibody (in house). For guanylyltransferase 
assays, CE IPs performed for 2.5 hours with 0.5μg CE 
antibody and RNA pol II IPs performed overnight with 
4μg Poll II (pan) antibody (Santa Cruz, sc-899). For 
endogenous CE and Pol II IPs, 20μl Protein G agarose 
bead slurry (Generon) added for 1 hour. IPs washed three 
times in 10mM Tris/Cl pH 7.5/150mM NaCl/0.5mM 
EDTA and eluted in F buffer/Laemmli buffer/0.1M DTT. 
Samples analysed by SDS-PAGE.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) performed 
as described [69]. Two 10cm plates of subconfluent cells 
used per ChIP. Cells crosslinked for 15 minutes. 1μg 
polyclonal CE antibody used per ChIP. 1μl (2% total) ChIP 
DNA or diluted input DNA used per 10μl quantitative 
PCR (SsoFast EvaGreen supermix, Bio-Rad). 3-fold input 
DNA dilutions used to calculate primer efficiency.
Reverse transcriptase PCR
RNA extracted using TRIzol (Life Technologies). 
cDNA synthesis reactions (20μl) containing 200ng RNA 
prepared using iScript cDNA synthesis kit (Bio-Rad). 
0.5ul cDNA per 5μl qPCR (SsoFast EvaGreen supermix, 
Bio-Rad). 3-fold cDNA dilutions used to calculate primer 
efficiency.
Guanylyltransferase activity assay
Guanylyltransferase activity assays performed 
as described [31]. Cell lysis and IPs performed in F 
buffer/5mM DTT. Washed IPs incubated with 3.75U/ml 
RNase A/ 150 U/ml RNase T1 for 15 minutes at 20ºC. 
IPs washed three times in reaction buffer (50mM Tris 
pH 7.8/5mM MgCl2/5mM DTT), then incubated for 1 
minute at 37°C in reaction buffer/6.7μM [α-32P]GTP 
(Perkin Elmer, BLU006H500UC). IPs analysed by SDS-
PAGE. Gels dried and CE-GMP intermediate quantified 
by phosphorimager.
Anchorage-independent cell growth assay
8,000 cells plated in 2ml growth medium/5% 
FBS/0.33% noble agar in 6 well plate on top of 0.6% noble 
agar base layer (2ml). Technical triplicates performed. 
Cells fed with 500μl growth medium/5% FBS alternate 
days. After 9-15 days, colonies in five fields from each 
well scored using graticule.
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